GLP-1 Receptor Agonists Reduce Mortality in Type 2 Diabetes Patients
Research suggests that mortality rates are lower in people with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to those not using these drugs.
A study by academics from Emory University in Atlanta found that GLP-1 RAs significantly protect people with type 2 diabetes and obstructive sleep apnoea (OSA) from mortality.
- The study examined the health outcomes of 1,799,261 adults with type 2 diabetes.
- Participants were placed into groups based on OSA status and medication prescription: metformin only, metformin and GLP-1 RAs, or with OSA and prescribed metformin and GLP-1 RAs.
The results revealed that participants prescribed GLP-1 RAs had reduced one-year mortality compared to those only prescribed metformin.
GLP-1 RAs significantly protect people with type 2 diabetes and obstructive sleep apnoea from mortality.
Author's summary: GLP-1 RAs reduce mortality in type 2 diabetes patients.
More News
- Strategies for a Virtual Panel Interview: How to Prepare and How to Act
- Dean Lewis Shares Statement Following Misconduct Allegations
- O Canada! Summer tourism numbers hit all-time high | RCI
- Stranger Things 5 Trailer Unleashes All-Out War in Hawkins Ahead of Final Season! | SPIN1038
- Shares of Navan Down 16% In Long-Awaited IPO Debut
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- Building Smarter, Flying Further: How HP’s Additive Manufacturing Team Is Changing the Way Drones Are Made
- Half of Illinois students reading at grade level, fewer in math under loosened standards
- ‘Grease’ Shines at the Little Theatre of Alexandria! - Falls Church News-Press Online
- Stranger Things 5 trailer shows way more than we were ready for